A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Public ClinicalTrials.gov record NCT03412747. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Randomized, Double-Blind Study With an Active-Controlled Initial Treatment Period Followed by a Dose-Blind Maintenance Treatment Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a study to compare the efficacy of bimekizumab versus adalimumab in the treatment of subjects with moderate to severe chronic plaque psoriasis (PSO).
Study identification
- NCT ID
- NCT03412747
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 478 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 26, 2018 (Actual)
- Primary completion
- Feb 7, 2019 (Actual)
- Completion
- Feb 26, 2020 (Actual)
- Last update posted
- Apr 15, 2026
2018 – 2020
United States locations
- U.S. sites
- 23
- U.S. states
- 15
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ps0008 957 | Glendale | Arizona | 85308 | — |
| Ps0008 927 | Los Angeles | California | 90033 | — |
| Ps0008 955 | San Diego | California | 92123 | — |
| Ps0008 943 | San Luis Obispo | California | 93405 | — |
| Ps0008 967 | Santa Monica | California | 90404 | — |
| Ps0008 939 | Danbury | Connecticut | 06810 | — |
| Ps0008 934 | Washington D.C. | District of Columbia | 20037 | — |
| Ps0008 906 | Boca Raton | Florida | 33486 | — |
| Ps0008 936 | Tampa | Florida | 33624 | — |
| Ps0008 900 | West Des Moines | Iowa | 50265 | — |
| Ps0008 905 | Overland Park | Kansas | 66215 | — |
| Ps0008 940 | Beverly | Massachusetts | 01844 | — |
| Ps0008 925 | Brighton | Massachusetts | 02135 | — |
| Ps0008 917 | Troy | Michigan | 48084 | — |
| Ps0008 908 | East Windsor | New Jersey | 08520 | — |
| Ps0008 961 | Rocky Mount | North Carolina | 27804 | — |
| Ps0008 935 | Winston-Salem | North Carolina | 27104-35 20 | — |
| Ps0008 932 | Oklahoma City | Oklahoma | 73112 | — |
| Ps0008 929 | Portland | Oregon | 97223 | — |
| Ps0008 945 | Greer | South Carolina | 29650 | — |
| Ps0008 931 | Dallas | Texas | 75231 | — |
| Ps0008 924 | Houston | Texas | 77004 | — |
| Ps0008 951 | Houston | Texas | 77004 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 54 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03412747, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 15, 2026 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03412747 live on ClinicalTrials.gov.